Nicox Stock

Nicox ROCE

The Return on Capital Employed (ROCE) of Nicox (ALCOX.PA) as of Aug 8, 2026 is -1,200.00 %. In the previous year, Return on Capital Employed (ROCE) was -84.95 % — a change of 1,312.64% (lower).

ROCE

-1,200.00 %

YoY

1,312.64%

Last updated:

In 2026, Nicox's return on capital employed (ROCE) was -1,200.00 %, a 1,312.64% increase from the -84.95 % ROCE in the previous year.

Access this data via the Eulerpool API

Nicox Stock analysis

What does Nicox do? Nicox SA is a French pharmaceutical company specializing in the development and commercialization of innovative therapy systems for eye diseases. It was founded in 1996 as a spin-off of Nestlé's research activities in the field of ophthalmology. The company's business model is based on the development of drugs based on nitric oxide (NO), a gaseous molecule that plays an important role in regulating blood flow and inflammation processes in the human body. Nicox SA's technology allows for the targeted release of NO donors in specific areas of the eye to reduce disease-related inflammation and damage. This provides a promising alternative to conventional therapies for a range of eye diseases. Nicox SA is divided into three business areas: Ophthalmology, Diagnostics, and Contracts. In the Ophthalmology segment, the company focuses on the development of drugs for the treatment of glaucoma, dry eye, and other eye diseases. Important products in this area include Vyzulta, a combination of an NO donor and a glaucoma drug, as well as NCX 470, an NO donor for the treatment of glaucoma. In addition, the company is working on the development of NCX 4251, an NO donor for the treatment of blepharitis, an inflammation of the eyelids. In the Diagnostics segment, Nicox SA offers innovative diagnostic tests for ophthalmology based on tear fluid analysis. These tests enable ophthalmologists to diagnose and monitor certain eye diseases more quickly and accurately. Key products in this area include AdenoPlus, a rapid test for diagnosing adenovirus conjunctivitis, and ClearSight, a test for monitoring glaucoma patients. The Contracts segment offers customized clinical research services for customers in the pharmaceutical industry. This segment is an important part of Nicox SA's strategy to generate additional revenue and finance the development of new therapies. Overall, Nicox SA has a strong pipeline of new therapies and diagnostic tests that allow the company to consolidate its position as a leading provider of eye medications. The company works closely with its industry and academic research partners to develop and bring innovative therapies to the market. In summary, Nicox SA is an innovative and rapidly growing company focusing on the development and commercialization of therapies for eye diseases. The company has a strong pipeline of new products and services and collaborates closely with its partners to strengthen its position in the industry. Nicox is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Nicox's Return on Capital Employed (ROCE)

Nicox's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Nicox's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Nicox's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Nicox’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Nicox stock

Return on Capital Employed (ROCE) of Nicox is -1,200.00 % in 2026.

Return on Capital Employed (ROCE) of Nicox changed from -84.95 % to -1,200.00 %, representing a 1,312.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Nicox since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Nicox with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — Nicox

All Key Metrics — Nicox